Compare FET & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FET | IVVD |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.7M | 437.1M |
| IPO Year | 2007 | 2021 |
| Metric | FET | IVVD |
|---|---|---|
| Price | $57.26 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 129.0K | ★ 2.4M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.64 | 79.02 |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $791,474,000.00 | $53,426,000.00 |
| Revenue This Year | $7.35 | $61.57 |
| Revenue Next Year | $6.95 | $41.42 |
| P/E Ratio | $149.56 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $14.44 | $0.49 |
| 52 Week High | $65.43 | $3.07 |
| Indicator | FET | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 47.25 | 34.88 |
| Support Level | $54.55 | $0.49 |
| Resistance Level | $63.59 | $1.14 |
| Average True Range (ATR) | 2.43 | 0.11 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 41.53 | 13.51 |
Forum Energy Technologies Inc is a products company, serving the oil, natural gas, industrial and renewable energy industries. The company designs, manufactures, and distributes products and engages in aftermarket parts supply and services that complement its product offering. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. It operates in two reporting segments, namely Drilling and Completions and Artificial Lift and Downhole. Revenue largely comes from Artificial Lift and Downhole segment.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.